What is KeyCorp's Forecast for Revvity FY2027 Earnings?

Key Points

• KeyCorp forecasts Revvity will earn $5.96 per share in FY2027. The firm maintains an “Overweight” rating and a $165 price target; its estimate is above the $5.42 consensus for the current full year.
• Revvity beat quarterly expectations, reporting EPS of $1.38 versus $1.30 expected and revenue of $728.9 million versus $694.7 million. Revenue increased 4.3% year over year.
• Analyst sentiment is mixed: the average rating is “Hold,” with an average price target of $133.86, while TD Cowen raised its target to $185 and kept a “Buy” rating.

Revvity Inc. (NYSE:RVTY - Free Report) - Stock analysts at KeyCorp issued their FY2027 EPS estimates for shares of Revvity in a research note issued on Tuesday, November 3rd. KeyCorp analyst P. Knight expects that the company will earn $5.96 per share for the year. KeyCorp has an "Overweight" rating and a $165.00 price target on the stock. The consensus estimate for Revvity's current full-year earnings is $5.42 per share.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.08. The company had revenue of $728.90 million for the quarter, compared to analyst estimates of $694.73 million. Revvity had a net margin of 8.61% and a return on equity of 8.64%. The company's revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 EPS.

Other equities research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Revvity from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday. TD Cowen upped their target price on shares of Revvity from $175.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, November 4th. Zacks Research upgraded Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Bank of America reiterated a "neutral" rating on shares of Revvity in a report on Wednesday, November 4th. Finally, Wall Street Zen downgraded Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. Six research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $133.86.

Revvity Price Performance

Shares of RVTY opened at $157.11 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.10 and a current ratio of 2.65. The stock has a 50 day simple moving average of $150.01 and a 200 day simple moving average of $114.10. Revvity has a 52-week low of $81.22 and a 52-week high of $171.74. The firm has a market capitalization of $17.54 billion, a PE ratio of 69.52, a P/E/G ratio of 2.77 and a beta of 1.08.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, January 22nd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity's payout ratio is currently 12.39%.

Insider Transactions at Revvity

In related news, insider Tajinder Vohra sold 7,330 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the company's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Jupiter Topco LLC bought a new position in shares of Revvity in the second quarter valued at $961,017,000. BlackRock Inc. bought a new stake in Revvity during the second quarter worth $852,070,000. EdgePoint Investment Group Inc. raised its position in Revvity by 3.1% during the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company's stock worth $771,044,000 after acquiring an additional 265,204 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company's stock valued at $731,386,000 after acquiring an additional 186,956 shares during the last quarter. Finally, State Street Corp lifted its stake in Revvity by 0.6% in the third quarter. State Street Corp now owns 4,370,897 shares of the company's stock valued at $668,266,000 after acquiring an additional 28,158 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company's work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.